RS50297B - Fenilfenantridini sa dejstvom inhibicije pde-iv - Google Patents

Fenilfenantridini sa dejstvom inhibicije pde-iv

Info

Publication number
RS50297B
RS50297B YUP-487/01A YUP48701A RS50297B RS 50297 B RS50297 B RS 50297B YU P48701 A YUP48701 A YU P48701A RS 50297 B RS50297 B RS 50297B
Authority
RS
Serbia
Prior art keywords
phenylphenanthridines
pde
inhibiting activity
cyclopropylmethoxy
methoxy
Prior art date
Application number
YUP-487/01A
Other languages
English (en)
Inventor
Gerhard Grundler
Beate Gutterer
Hermann Amschler
Rolf Beume
Hildegard Boss
Hans-Peter Kley
Dieter Flockerzi
Armin Hatzelmann
Daniela Bundschuh
Original Assignee
Nycomed Gmbh.,
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nycomed Gmbh., filed Critical Nycomed Gmbh.,
Publication of YU48701A publication Critical patent/YU48701A/sh
Publication of RS50297B publication Critical patent/RS50297B/sr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/04—Drugs for disorders of the urinary system for urolithiasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
    • C07D211/14—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C07D221/06—Ring systems of three rings
    • C07D221/10—Aza-phenanthrenes
    • C07D221/12—Phenanthridines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Reproductive Health (AREA)
  • Toxicology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Communicable Diseases (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Transplantation (AREA)
  • Otolaryngology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)

Abstract

Jedinjenje formule u kojima R1 je metoksi, R2 je metoksi, R3, R31, R4, R5 i R51 su vodonici, R6 je 3-ciklopropilmetoksi, R13 je vodonik, R20 je 4-ciklopropilmetoksi, i soli, N-oksidi i soli N-oksida tih jedinjenja koji se koriste kao njihovi solvati. Prijava sadrži 6 zavisnih patenata
YUP-487/01A 1999-01-15 2000-01-12 Fenilfenantridini sa dejstvom inhibicije pde-iv RS50297B (sr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP99100694 1999-01-15

Publications (2)

Publication Number Publication Date
YU48701A YU48701A (sh) 2004-05-12
RS50297B true RS50297B (sr) 2009-09-08

Family

ID=8237351

Family Applications (1)

Application Number Title Priority Date Filing Date
YUP-487/01A RS50297B (sr) 1999-01-15 2000-01-12 Fenilfenantridini sa dejstvom inhibicije pde-iv

Country Status (32)

Country Link
US (1) US6476025B1 (sr)
EP (2) EP1147089B1 (sr)
JP (1) JP4653314B2 (sr)
KR (1) KR100720906B1 (sr)
CN (1) CN1152864C (sr)
AT (1) ATE312081T1 (sr)
AU (1) AU774868B2 (sr)
BG (1) BG65126B1 (sr)
BR (1) BR0007527B1 (sr)
CA (1) CA2359440C (sr)
CY (1) CY1106436T1 (sr)
CZ (1) CZ300366B6 (sr)
DE (1) DE60024581T2 (sr)
DK (1) DK1147089T3 (sr)
EA (1) EA003780B1 (sr)
EE (1) EE05105B1 (sr)
ES (1) ES2254132T3 (sr)
HK (1) HK1040997B (sr)
HR (1) HRP20010578A2 (sr)
HU (1) HU227624B1 (sr)
ID (1) ID29070A (sr)
IL (2) IL144026A0 (sr)
NO (1) NO320182B1 (sr)
NZ (1) NZ512872A (sr)
PL (1) PL205670B1 (sr)
RS (1) RS50297B (sr)
SI (1) SI1147089T1 (sr)
SK (1) SK286946B6 (sr)
TR (2) TR200101938T2 (sr)
UA (1) UA69436C2 (sr)
WO (1) WO2000042020A1 (sr)
ZA (1) ZA200104864B (sr)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002006238A1 (en) * 2000-07-14 2002-01-24 Altana Pharma Ag Cycloalkyl - or cycloalkylmethyl-substituted 6-phenylphenanthridines
PL374014A1 (en) * 2002-08-17 2005-09-19 Altana Pharma Ag Novel phenanthridines having pde 3/4 inhibiting properties
WO2004019945A1 (en) * 2002-08-29 2004-03-11 Altana Pharma Ag 3-hydroxy-6-phenylphenanthridines as pde-4 inhibitors
EP1539164B1 (en) 2002-08-29 2006-12-20 ALTANA Pharma AG 2-hydroxy-6-phenylphenanthridines as pde-4 inhibitors
US6894061B2 (en) 2002-12-04 2005-05-17 Wyeth Substituted dihydrophenanthridinesulfonamides
JP2007500686A (ja) * 2003-07-31 2007-01-18 アルタナ　ファルマ　アクチエンゲゼルシャフト 新規の６−フェニルフェナントリジン
EP1658270A1 (en) * 2003-07-31 2006-05-24 ALTANA Pharma AG Novel 6-phenylphenantridines
AU2004269923B2 (en) * 2003-09-05 2010-05-13 Takeda Gmbh Use of PDE4 inhibitors for the treatment of diabetes mellitus
ES2400823T3 (es) * 2004-02-18 2013-04-12 Takeda Gmbh Nuevas hidroxi-6-fenilfenantridinas sustituidas con guanidinilo como inhibidores eficaces de fosfodiesterasa (PDE) 4
AR049419A1 (es) * 2004-03-03 2006-08-02 Altana Pharma Ag Hidroxi-6-fenilfenantridinas sustituidas con heterociclilo
SG182194A1 (en) 2004-03-03 2012-07-30 Nycomed Gmbh Novel hydroxy-6-heteroarylphenanthridines and their use as pde4 inhibitors
BRPI0508361A (pt) * 2004-03-09 2007-11-20 Altana Pharma Ag hidróxi-6-fenilfenantridinas substituìdas por isoamido
CA2558391A1 (en) * 2004-03-10 2005-09-22 Altana Pharma Ag Novel amido-substituted hydroxy-6-phenylphenanthridines and their use as pde4 inhibitors
AU2005221831A1 (en) * 2004-03-10 2005-09-22 Nycomed Gmbh Novel thio-containing hydroxy-6-phenylphenanthridines and their use as PDE4 inhibitors
BRPI0508471A8 (pt) * 2004-03-10 2019-01-15 Altana Pharma Ag compostos de hidróxi-6-fenilfenantidinas substituídas por difluoroetóxi, composição farmacêutica e uso para a produção dos mesmos
EP1791847A2 (en) * 2004-09-08 2007-06-06 Altana Pharma AG Novel 3-thia-10-aza-phenanthrene derivatives
US7411093B2 (en) * 2004-12-20 2008-08-12 Hoffman-La Roche Inc. Aminocycloalkanes as DPP-IV inhibitors
JP5478828B2 (ja) 2005-03-02 2014-04-23 タケダ ゲゼルシャフト ミット ベシュレンクテル ハフツング ６−ヘテロシクリル置換されたヘキサヒドロフェナントリジン誘導体の新規の塩
NZ560269A (en) 2005-03-08 2010-12-24 Nycomed Gmbh Roflumilast for the treatment of diabetes mellitus
CA2599368A1 (en) * 2005-03-09 2006-09-14 Nycomed Gmbh Amido-substituted 6-phenylphenanthridines
EP2207540B1 (en) 2007-10-04 2014-02-26 F. Hoffmann-La Roche AG Cyclopropyl aryl amide derivatives and uses thereof
US8629274B2 (en) 2011-12-21 2014-01-14 Novira Therapeutics, Inc. Hepatitis B antiviral agents
TW201920090A (zh) 2012-08-28 2019-06-01 愛爾蘭商健生科學愛爾蘭無限公司 胺磺醯基－芳醯胺類及其做為治療ｂ型肝炎之醫藥劑的用途
SI2961732T1 (sl) 2013-02-28 2017-07-31 Janssen Sciences Ireland Uc Sulfamoil-arilamidi in njihova uporaba kot zdravila za zdravljenje hepatitisa B
MX353412B (es) 2013-04-03 2018-01-10 Janssen Sciences Ireland Uc Derivados de n-fenil-carboxamida y su uso como medicamentos para el tratamiento de la hepatitis b.
PT2997019T (pt) 2013-05-17 2018-11-21 Janssen Sciences Ireland Uc Derivados de sulfamoíltiofenamida e o seu uso como medicamentos para o tratamento da hepatite b
JO3603B1 (ar) 2013-05-17 2020-07-05 Janssen Sciences Ireland Uc مشتقات سلفامويل بيرولاميد واستخدامها كادوية لمعالجة التهاب الكبد نوع بي
WO2015011281A1 (en) 2013-07-25 2015-01-29 Janssen R&D Ireland Glyoxamide substituted pyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis b
SG11201602748XA (en) 2013-10-23 2016-05-30 Janssen Sciences Ireland Uc Carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis b
US9169212B2 (en) 2014-01-16 2015-10-27 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
US10392349B2 (en) 2014-01-16 2019-08-27 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
MX2016009449A (es) 2014-02-05 2016-10-13 Novira Therapeutics Inc Terapia de combinacion para el tratamiento de infecciones por virus de la hepatitis b (vhb).
CA2932551A1 (en) 2014-02-06 2015-08-13 Janssen Sciences Ireland Uc Sulphamoylpyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis b
WO2016149581A1 (en) 2015-03-19 2016-09-22 Novira Therapeutics, Inc. Azocane and azonane derivatives and methods of treating hepatitis b infections
US10875876B2 (en) 2015-07-02 2020-12-29 Janssen Sciences Ireland Uc Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
WO2017059059A1 (en) 2015-09-29 2017-04-06 Novira Therapeutics, Inc. Crystalline forms of a hepatitis b antiviral agent
BR112018071048A2 (pt) 2016-04-15 2019-05-07 Janssen Sciences Ireland Uc combinações e métodos que compreendem um inibidor da montagem de capsídeos
US10973801B2 (en) 2018-03-14 2021-04-13 Janssen Sciences Ireland Unlimited Company Capsid assembly modulator dosing regimen
BR112021015618A2 (pt) 2019-02-22 2021-10-05 Janssen Sciences Ireland Unlimited Company Derivados de amida úteis no tratamento da infecção pelo hbv ou doenças induzidas pelo hbv
CN113795486A (zh) 2019-05-06 2021-12-14 爱尔兰詹森科学公司 用于治疗hbv感染或hbv诱发的疾病的酰胺衍生物

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3899494A (en) 1970-05-13 1975-08-12 Sandoz Ltd Substituted 6-phenyl benzo-naphthyridines
KR100454781B1 (ko) * 1996-01-31 2005-04-08 알타나 파마 아게 신규한페난트리딘
US6127378A (en) 1996-03-26 2000-10-03 Byk Gulden Lomberg Chemische Fabrik Gmbh Phenanthridines substituted in the 6 position
ATE224386T1 (de) * 1996-03-26 2002-10-15 Altana Pharma Ag Neue in 6-position substituierte phenanthridine
EE03829B1 (et) 1996-11-11 2002-08-15 Byk Gulden Lomberg Chemische Fabrik Gmbh Bensonaftüridiinid, nende kasutamine bronhiaalravimi valmistamiseks ning neid sisaldav ravim
DE69817548T2 (de) 1997-03-07 2004-06-17 Altana Pharma Ag Tetrazole derivate
WO1998055481A1 (en) 1997-06-03 1998-12-10 Byk Gulden Lomberg Chemische Fabrik Gmbh Benzonaphthyridine
EP0998460B1 (en) * 1997-07-25 2004-03-03 ALTANA Pharma AG Novel tetrazole derivatives
JP2001510827A (ja) * 1997-07-25 2001-08-07 ビイク グルデン ロンベルク ヒエーミツシエ フアブリーク ゲゼルシヤフト ミツト ベシユレンクテル ハフツング 置換６−フェニルフェナントリジン
EP1147088B1 (en) * 1999-01-15 2006-01-04 ALTANA Pharma AG 6-arylphenanthridines with pde-iv inhibiting activity
ATE294793T1 (de) * 1999-01-15 2005-05-15 Altana Pharma Ag Phenantrhridin-n-oxides mit pde-iv hemmender wirkung
WO2000042017A1 (en) * 1999-01-15 2000-07-20 Byk Gulden Lomberg Chemische Fabrik Gmbh Phenanthridine-n-oxides with pde-iv inhibiting activity

Also Published As

Publication number Publication date
HK1040997B (zh) 2006-07-14
HUP0105001A2 (hu) 2002-04-29
EP1650193A2 (en) 2006-04-26
US6476025B1 (en) 2002-11-05
NO320182B1 (no) 2005-11-07
CA2359440A1 (en) 2000-07-20
SK286946B6 (sk) 2009-08-06
DK1147089T3 (da) 2006-04-10
AU774868B2 (en) 2004-07-08
WO2000042020A1 (en) 2000-07-20
BG105561A (en) 2001-12-29
DE60024581T2 (de) 2006-08-10
ID29070A (id) 2001-07-26
TR200501553T2 (tr) 2005-06-21
EP1650193A3 (en) 2006-10-04
JP4653314B2 (ja) 2011-03-16
AU2289600A (en) 2000-08-01
EP1147089A1 (en) 2001-10-24
EP1147089B1 (en) 2005-12-07
PL348925A1 (en) 2002-06-17
CN1152864C (zh) 2004-06-09
HU227624B1 (en) 2011-09-28
BR0007527A (pt) 2001-12-04
CZ300366B6 (cs) 2009-05-06
BR0007527B1 (pt) 2011-12-27
HUP0105001A3 (en) 2002-10-28
UA69436C2 (uk) 2004-09-15
EE05105B1 (et) 2008-12-15
CZ20012248A3 (cs) 2001-09-12
ATE312081T1 (de) 2005-12-15
DE60024581D1 (de) 2006-01-12
EA200100731A1 (ru) 2002-02-28
SK9802001A3 (en) 2001-12-03
TR200101938T2 (tr) 2001-12-21
BG65126B1 (bg) 2007-03-30
NO20013341L (no) 2001-09-17
JP2002534508A (ja) 2002-10-15
NO20013341D0 (no) 2001-07-05
EA003780B1 (ru) 2003-08-28
SI1147089T1 (sl) 2006-04-30
ES2254132T3 (es) 2006-06-16
NZ512872A (en) 2003-07-25
IL144026A (en) 2007-05-15
PL205670B1 (pl) 2010-05-31
HRP20010578A2 (en) 2002-08-31
CY1106436T1 (el) 2011-10-12
IL144026A0 (en) 2002-04-21
ZA200104864B (en) 2003-04-15
EE200100350A (et) 2002-10-15
YU48701A (sh) 2004-05-12
CA2359440C (en) 2009-04-14
KR100720906B1 (ko) 2007-05-25
KR20010086164A (ko) 2001-09-08
CN1336919A (zh) 2002-02-20
HK1040997A1 (en) 2002-06-28

Similar Documents

Publication Publication Date Title
RS50297B (sr) Fenilfenantridini sa dejstvom inhibicije pde-iv
MX9800867A (es) Halogenobencimidazoles y su empleo como microbicidas.
TW359669B (en) Benzazepine derivatives
TW368397B (en) Oxaborole derivatives and their use as antimicrobial agent
ES8703142A1 (es) Proceso para preparar un derivado del bencimidazol.
ATE171158T1 (de) Substituierte phenylverbindungen
YU20199A (sh) Heterociklični sukcinimidi i njihova primena kao metaloproteinaznih inhibitora
CA2286723A1 (en) Tricyclic compounds
MY125359A (en) Bicyclic heterocyclic substituted phenyl oxazolidinone antibacterials, and related compositions and methods.
MX9709951A (es) Derivados de benzamida y su uso como antagonistas de vasopresina.
HK1087112A1 (en) Tricyclic compounds, their production and use
PT1140916E (pt) Acetais heteroarilo ciclicos
NZ514662A (en) Amine derivatives
ES8603711A1 (es) Procedimiento para preparar compuestos benzimidazoles 2-piridilmetil-tio y sulfinil substituidos
SI1042319T1 (en) Dihydrobenzofurans
ATE245642T1 (de) Benzamide mit tetrahydrofuranyloxy-substituenten als inhibitoren der phosphodiesterase 4
DE69511260D1 (en) Bicyclische amidinderivate als no-synthetase inhibitoren
RS49965B (sr) Supstituisani bisindolmaleimidi za inhibiciju ćelijske proliferacije
MY100115A (en) Nitrogen containing heterocyclic compounds, and their production and use.
WO2002000638A8 (en) Substituted phthalides as anti-convulsive drugs
WO2004072088A3 (en) Phosphine compound, intermediate, palladium-complex, and use thereof
ATE247660T1 (de) Furopyridinderivate und ihre therapeutische verwendung
EP1116486A4 (en) MEDICAL COMPOSITION CONTAINING NITROETHENAMINE DERIVATIVES OR SALTS AS ACTIVE INGREDIENTS
WO2002033216A3 (en) Corrosion inhibitor-drag reducer combinations
NZ332713A (en) Substituted 1,3-benzodioxoles and use as antidiabetic, antihyperglycemic, and antiobesity agents